Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (11): 984-989.doi: 10.35541/cjd.20201110

• Original Articles • Previous Articles     Next Articles

Analysis of fever and drug-induced liver injury in 63 patients with severe drug eruptions

Yao Cuiling1, Wang Zihan2, Hu Jingjing3, Gao Yu1, Ding Changling4   

  1. 1Department of Dermatology, Binzhou Medical University Hospital, Binzhou 256603, Shandong, China; 2Department of Dermatology, Yantaishan Hospital, Yantai 264000, Shandong, China; 3Department of Dermatology, Zaozhuang Dermatology and STD Prevention and Treatment Hospital, Zaozhuang 277100, Shangdong, China; 4Department of Pharmacy, Binzhou Medical University Hospital, Binzhou 256603, Shandong, China
  • Received:2020-11-20 Revised:2021-08-27 Online:2021-11-15 Published:2021-11-01
  • Contact: Gao Yu E-mail:binyigaoyu@126.com
  • Supported by:
    Shandong Medical and Health Science and Technology Program (2014WS0488); Shandong Adverse Drug Reaction Monitoring Center Project (2017SDADRKY06); Science and Technology Plan Project of Binzhou Medical University (BY2013KJ12)

Abstract: 【Abstract】 Objective To investigate characteristics of fever and drug-induced liver injury (DILI) in inpatients with severe drug eruptions. Methods A retrospective analysis was carried out on clinical data collected from 63 inpatients with severe drug eruptions from June 2007 to June 2020, and their characteristics of fever and DILI were investigated. Two-independent-sample t test or Kruskal-Wallis H test was used for intergroup comparison of measurement data, and intergroup comparison of enumeration data was performed using chi-square test or Fisher′s exact test. Results Among the 63 patients with severe drug eruptions, 54 developed fever; low, moderate and high/ultra-high fever all occurred in about one third of the patients; of 17 patients with high/ultra-high fever, 16 sufferred from Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or drug hypersensitivity syndrome (DHS); 45 had irregular fever; fever duration ranged from 1 to 14 days in 51 patients; there were no significant differences in the fever grade or duration among the patients with different clinical types of drug eruptions (P = 0.303, 0.719, respectively); rashes occurred earlier than or at the same time as fever in 92.59% of the patients. DILI occurred in 11 patients, 8 of whom had hepatocellular injury at admission, including 5 with DHS, 2 with SJS and 1 with TEN; 6 patients were accompanied by low, moderate or high fever, with the fever duration being 7.33 ± 4.97 days, and they all had grade 1 liver injury; liver function retesting at discharge showed complete recovery in 5 patients, improvement in 1, as well as conversion from hepatocellular injury to mixed liver injury in 1, and 1 patient did not undergo the liver function retesting due to against-medical-advice discharge. The other 3 patients had cholestatic liver injury, all of whom were diagnosed with DHS and accompanied by high or ultra-high fever, wtih the fever duration being 8.33 ± 3.51 days, and 1 patient had grade 4 liver injury (acute liver failure); liver function was improved in all the 3 patients at discharge. Conclusions Patients with severe drug eruptions are prone to be accompanied by various types of fever, irregular fever is more common, fever usually lasts 2 weeks, and rashes often occur earlier than or at the same time as fever. DILI can occur in patients with severe drug eruptions, and is usually accompanied by fever; hepatocellular injury is more common, and prone to be improved rapidly; cholestatic liver injury is characterized by severe clinical symptoms and a long disease course, and most frequently occurs in patients with DHS.

Key words: Drug eruptions, Drug-induced liver injury, Fever, Severe drug eruptions, Cholestatic liver injury